Protalix Alleviates Ulcerative Colitis, Sending Some Cases Into Remission, Phase 2 Trial Shows

Protalix Alleviates Ulcerative Colitis, Sending Some Cases Into Remission, Phase 2 Trial Shows
Protalix BioTherapeutics’ OPRX-106 alleviated ulcerative colitis and in some cases sent it into remission, a Phase 2 clinical trial shows . OPRX-106 is a TNF inhibitor that Protalix scientists grew from a plant cell to resist gastrointestinal degradation better than proteins from animals cells. TNF inhibitors are used worldwide to treat inflammatory bowel disease, which includes

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *